Outlook Therapeutics slides after US FDA declines its eye disease drug

Outlook Therapeutics

31/12/2025 22:21

** Outlook Therapeutics OTLK.O shares dive ~68% to $0.49 in extended trading after the U.S. Food and Drug Administration declined to approve its eye disease drug

** OTLK was testing drug Lytenava, for the treatment of wet age-related macular degeneration, a chronic eye disorder that causes blurred vision or a blind spot in the patient's visual field

** U.S. FDA had initially declined to approve the eye drug in 2023 and again declined to approve it in August 2025

** As of last close, stock down ~16.4% YTD

 (Reporting by Prakhar Srivastava in Bengaluru)

 ((Prakhar.srivastava2@thomsonreuters.com))